NASDAQ · IONS
Ionis Pharmaceuticals, Inc.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
Loading market information…
NASDAQ · ETON · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eton Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Eton Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.31. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eton Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | $0.07-22.22% vs estimate | $17.28M+14.22% vs estimate |
|---|
| Q4 2024 | Mar 18, 2025 | -$0.020.0% vs estimate | $11.65M-18.73% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | $0.02+400.0% vs estimate | $10.32M-1.96% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $70.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$16.78-$0.42 (-2.44%)
Ultragenyx Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$12.13-$0.13 (-1.06%)
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.16% below the high.
$1.48-$0.01 (-0.34%)
Lexicon Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
$10.36+$0.05 (+0.48%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.12% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$10.95+$0.08 (+0.74%)
Fennec Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.36% below the high.
